De-escalation Pathways

For Use in The Following Patients

  • Patients with acute myeloid leukemia/myelodysplastic syndromes or who have undergone autologous hematopoietic stem-cell transplant with myeloablative conditioning regimens

  • Patients at high risk for febrile neutropenia or profound, protracted neutropenia

    • Absolute neutrophil count (ANC) less than or equal to 0.5 x 10⁹ cells/L for greater than or equal to 7 days

Classify Patient